FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average	burden									

0.5

hours per response

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Kalb Michael Wayne						2. Issuer Name and Ticker or Trading Symbol AMARIN CORP PLC\UK [ AMRN ]							(Ch	eck all appli Direct	tionship of Reporting Persall applicable) Director Officer (give title below)  SVP and C		on(s) to Issi 10% Ov Other (s	wner	
(Last) (First) (Middle) C/O AMARIN PHARMA, INC.						3. Date of Earliest Transaction (Month/Day/Year) 01/09/2019											below)	peony	
1430 ROUTE 206					_ 4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. 1	6. Individual or Joint/Group Filing (Check Applicable					
(Street) BEDMI	Street) BEDMINSTER NJ 07921					,,						Line	X Form	Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(	State)	(Zip)											Perso	n				
		Та	ble I - I	Non-De	rivativ	ve Se	cur	ities Ad	cquire	d, D	isposed o	f, or Be	neficiall	y Owned					
1. Title of Security (Instr. 3)  2. Transactio Date (Month/Day/Y				Execution Date,				s Acquired (A) or f (D) (Instr. 3, 4 and			ies cially Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership					
									Code	v	Amount	(A) or (D)	Price		ed ction(s) 3 and 4)			(Instr. 4)	
Ordinary Shares <sup>(1)(2)</sup> 01/09/202				/2019	9		M		200,000	A	\$2.19	217	486 <sup>(3)</sup> D <sup>(4)</sup>		D <sup>(4)</sup>				
Ordinary Shares <sup>(1)(2)</sup> 01/09/20:				/2019	19		S		200,000	D	\$15.2554	l <sup>(5)</sup> 17	17,486 <sup>(3)</sup>		D <sup>(4)</sup>				
			Table								posed of, , converti			Owned					
1. Title of Derivative Security (Instr. 3)  2. Conversio or Exercis Price of Derivative Security			Execution (ear) if any			ransaction ode (Instr.				6. Date Exercisable and Expiration Date (Month/Day/Year)			nd Amount ties ng e Security nd 4)	8. Price of Derivative Security (Instr. 5)		e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	ion(s)			
Stock Option (Right to	\$2.19	01/09/2019			М			200,000	(6	5)	07/01/2026	Ordinary Shares <sup>(2)</sup>	200,000	\$0.00	275,0	00	D		

## **Explanation of Responses:**

- 1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- 2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- 3. Includes 1,006 shares purchased under the Issuer's 2017 Employee Stock Purchase Plan (the "ESPP") on May 31, 2018, and 1,484 shares purchased under the ESPP on November 30, 2018.
- 4. Please see the section titled "Remarks" below for additional information.
- 5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$15.25 to \$15.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 6. On July 1, 2016, the Reporting Person was granted an option to purchase 625,000 Ordinary Shares under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). The shares subject to this option shall vest as follows: 25% of the total number of underlying shares shall vest on July 1, 2017, and the remaining 75% of the underlying shares shall vest ratably over the subsequent 36 months.

## Remarks:

Remarks: In the case of a Change of Control (as defined in the Plan), the grants described in this Form 4 vest in full. As of the date of this Form 4, the Reporting Person owns or holds the right to acquire an aggregate of 898,486 Ordinary Shares of the Issuer in the form of Ordinary Shares, stock options and Restricted Stock Units granted under the Plan.

/s/ Joseph Kennedy, by power of attorney

01/11/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.